41. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer : a single institution retrospective analysisMartina Reberšek, Marko Boc, Petra Škerl, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Srdjan Novaković, Janja Ocvirk, 2011, izvirni znanstveni članek Ključne besede: rak (medicina), debelo črevo, danka, zdravljenje Objavljeno v DiRROS: 18.03.2024; Ogledov: 127; Prenosov: 49 Celotno besedilo (461,04 KB) |
42. Sinonasal inverted papilloma associated with squamous cell carcinomaJasna But-Hadžić, Klemen Jenko, Mario Poljak, Boštjan Kocjan, Nina Gale, Primož Strojan, 2011, izvirni znanstveni članek Ključne besede: rak (medicina), papiloma virusi, nosna votlina, karcinom, zdravljenje, radioterapija Objavljeno v DiRROS: 18.03.2024; Ogledov: 163; Prenosov: 46 Celotno besedilo (513,64 KB) |
43. Lymphedema following cancer therapy in Slovenia : a frequently overlooked condition?Tanja Planinšek Ručigaj, Nada Kecelj, Vesna Tlaker Žunter, 2010, izvirni znanstveni članek Povzetek: Introduction. Secondary lymphedema following cancer therapy is a frequent, often painful, quality of life disturbing condition, reducing the patients' mobility and predisposing them to complications, e.g. infections and malignancies. The critical aspect of lymphedema therapy is to start as soon aspossible to prevent the irreversible tissue damage. Patients and methods. Weperformed a retrospective study of patients with lymphedema, treated at the Department of Dermatovenereology, University Medical Center Ljubljana, from January 2002 to June 2010. The patientsć demographic and medical data were collected, including type of cancer, type and stage of lymphedema, and time tofirst therapy of lymphedema. The number of referred patients with lymphedema following the therapy of melanoma, breast cancer, and uterine/cervical cancer, was compared to the number of patients expected to experience lymphedema following cancer therapy, calculated from the incidence reported in the literature. Results. In the period of 8.5 years, 543 patients (432 females, 112 males) with lymphedema were treated. The results show that probably many Slovenian patients with secondary lymphedema following cancer therapy remain unrecognized and untreated or undertreated. In the majority of our patients, the management of lymphedema was delayedč on average, the patients first received therapy for lymphedema 3.6 years after the first signsof lymphedema. Conclusions. To avoid a delay in diagnosis and therapy, and the complications of lymphedema following cancer therapy, the physician should actively look for signs or symptoms of lymphedema during the follow-up period, and promptly manage or refer the patients developing problems. Ključne besede: rak (medicina), zdravljenje, limfedem Objavljeno v DiRROS: 18.03.2024; Ogledov: 121; Prenosov: 36 Celotno besedilo (416,52 KB) |
44. Imaging findings in bisphosphonate-induced osteonecrosis of the jawsKatarina Šurlan Popović, Miha Kočar, 2010, izvirni znanstveni članek Ključne besede: rak (medicina), bisfosfonati, radiologija, zdravljenje, čeljustnica, nekroze, diagnostika Objavljeno v DiRROS: 18.03.2024; Ogledov: 132; Prenosov: 40 Celotno besedilo (737,45 KB) |
45. Urine and bladder washing cytology for detection of urothelial carcinoma : standard test with new possibilitiesMargareta Strojan Fležar, 2010, pregledni znanstveni članek Povzetek: Background. Light microscopic evaluation of cell morphology in preparations from urine or bladder washing containing exfoliated cells is a standard and primary method for the detection of bladder cancer and also malignancy from other parts of the urinary tract. The cytopathologic examination is a valuablemethod to detect an early recurrence of malignancy or new primary carcinoma during the follow-up of patients after the treatment of bladder cancer. Conclusions. Characteristic cellular and nuclear signs of malignancy indicate invasive or in situ urothelial carcinoma or high-grade papillary urothelial carcinoma. However, low sensitivity of the method reflects the unreliable cytopathologic diagnosis of low-grade urothelial neoplasms as cellular and nuclear signs of malignancy in these neoplasms are poorly manifested. Many different markers were developed to improve the diagnosis of bladder carcinoma on urinary samples. UroVysionT test is among the newest and most promising tests. By the method of in situ hybridization one can detect specific cytogenetic changes of urothelial carcinoma. Ključne besede: rak (medicina), diagnostika, citološka diagnostika, sečni mehur Objavljeno v DiRROS: 18.03.2024; Ogledov: 114; Prenosov: 35 Celotno besedilo (589,07 KB) |
46. Incidenca raka v prvem letu epidemije covida-19Vesna Zadnik, Tina Žagar, Nika Bric, Mojca Birk, Amela Duratović Konjević, Ana Mihor, Katarina Lokar, Sonja Tomšič, 2023, strokovni članek Povzetek: Uvod: Število novih diagnoz raka (incidenca) se v Sloveniji v zadnjem desetletju povečuje za povprečno 1,6 % na leto. V letu 2020, prvem letu omejitvenih ukrepov zaradi epidemije covida19, smo s platformo OnKOvid predvideli 3–8-odstotni padec novih diagnoz raka. Namen je predstaviti uradno incidenco raka za Slovenijo za leto 2020 in ugotoviti, kolikšen je bil dejansko manko novih diagnoz raka. Metode: V Registru raka Republike Slovenije smo v skladu z mednarodnimi pravili registrirali vse nove primere raka pri prebivalcih s stalnim prebivališčem v Sloveniji. Primerjali smo jih z registrirano incidenco za 2019, modelno incidenco za 2020, preliminarnimi rezultati OnKovida in dostopnimi rezultati incidence iz registrov raka iz drugih držav. Rezultati: V letu 2020 je za rakom zbolelo 15.096 oseb v Sloveniji (7.034 žensk, 8.002 moška). Glede na modelno oceno incidence za leto 2020 gre za manko 1.854 oseb (10,9 %; 11,6 % žensk, 10,4 % moških). Pri tem je za 10,5 % manj ugotovljenih rakov v omejenem stadiju, najbolj izrazito v starosti 50–69 let (za 13,2 %). Upad je primerljiv s poročili iz Anglije, ZDA in Kanade ter deloma večji kot na Škotskem in Švedskem. Najbolj izrazit upad novih diagnoz raka ugotavljamo pri nemelanomskem kožnem raku (23 %, najbolj po 50. letu), raku prostate (15,9 %, najbolj v omejenem stadiju), pljučnem raku (8,9 %, 60–64 let, v razširjenem stadiju), raku dojk (8,3 %, 45–64 let), ne-Hodgkinovem limfomu (9 %) in levkemijah (11,6 %). Pri kožnem melanomu, raku debelega črevesa in danke ni bilo primanjkljaja. Zaključek: Upad incidence raka v letu 2020 gre verjetno na račun omejitvenih ukrepov, reorganizacije zdravstva in z zdravjem povezanega vedenja med epidemijo covida-19, beležijo jo v več državah. Med epidemijami je potrebno nemoteno izvajanje onkologije. Ključne besede: rak, incidenca, register raka, epidemija, covid-19 Objavljeno v DiRROS: 26.02.2024; Ogledov: 213; Prenosov: 46 Celotno besedilo (301,68 KB) |
47. |
48. |
49. |
50. |